Optimal Application Timing of ADC Drugs for Advanced Breast Cancer

计划入组 120 人 · 首次发布于 2026 年 6 月 18 日

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

计划入组 72 人 · 首次发布于 2025 年 11 月 21 日

A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

计划入组 96 人 · 首次发布于 2026 年 7 月 30 日

repurposed anticancer drugs

masked ADC

PSMA-ADC-1301

ADC Therapeutics

Switzerland

ADC Therapeutics America, Inc.

United States

AARTI DRUGS LIMITED

India

Akari Reports Breakthrough Preclinical Data for AKTX-101 in KRAS-Mutated Pancreatic Cancer, Stock Surges 50%

Huonslab Patents Subcutaneous ADC Formulation Using HyDIFFUZE Platform, Demonstrating 126% Increase in Systemic Drug Exposure

Elahere Demonstrates Promising Results in Platinum-Sensitive Ovarian Cancer